• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.87% Nasdaq Up0.34%

    Exelixis, Inc. (EXEL)

    1.30 Down 0.03(2.26%) 4:00PM EST
    |After Hours : 1.30 0.00 (0.00%) 4:47PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Exelixis, Inc.
    210 East Grand Avenue
    South San Francisco, CA 94080
    United States - Map
    Phone: 650-837-7000
    Fax: 650-837-8300
    Website: http://www.exelixis.com

    Index Membership:N/A
    Full Time Employees:227

    Business Summary 

    Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Exelixis, Inc.

    Corporate Governance 
    Exelixis, Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 5; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Stelios Papadopoulos Ph.D., 66
    Co-Founder, Chairman and Member of Audit Committee
    Mr. Michael M. Morrissey Ph.D., 53
    Chief Exec. Officer, Pres and Director
    Ms. Pamela A. Simonton J.D., LL.M, 64
    Exec. VP
    Dr. Gisela M. Schwab M.D., 57
    Chief Medical Officer and Exec. VP
    Mr. Frank L. Karbe , 45
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders